MENU

Clinical-Stage BioTech Drug Stocks Declined 13% In June

Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read "Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know" to better understand why psychedelic stocks are in decline.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story